Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)

NCT02478229•University Health Network, Toronto

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Hepatitis C Viral Infection

Interventions

Sofosbuvir (SOF) and Ledipasvir (LDV)

Locations

Canada

Locations (1)

University Health Network

Toronto, Ontario, Canada

Key Dates

Start Date

June 1, 2015

Primary Completion Date

April 1, 2016

Completion Date

August 1, 2016

Last Updated

August 8, 2016

Sponsors

Lead Sponsor

University Health Network, Toronto

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 8, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions